Premium
ERLOTINIB 100MG VERSUS 150MG IN PATIENTS WITH NON‐SMALL‐CELL LUNG CANCER HARBORING MUTATIONS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR: A MULTICENTER OPEN‐LABEL, RANDOMIZED PHASE 2 TRIAL
Publication year - 2019
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.13699_141
Subject(s) - erlotinib , medicine , epidermal growth factor receptor , open label , erlotinib hydrochloride , lung cancer , epidermal growth factor , oncology , randomized controlled trial , cancer , receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom